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From the Celgene CorporationTwo reports in a recent issue, by Arpinati et al. [1] and the body, every sample is likely to contain 1 or more. An
Goldman [2], touch on how to interpret results of high-
sensitivity PCR testing for BCR/ABL1 mRNA transcripts in
persons with chronic myelogenous leukemia (CML). The
authors sensibly argue that an occasional positive test should
not be interpreted as indicating clinical relapse and should
not precipitate an intervention. They then offer intriguing,
sometimes complex, explanations of this observation.
Might I add another? Ten years ago, in an interesting,
dense, and completely ignored report by Butturini et al.[3]
we showed, using mathematical modeling, that when there
are few residual leukemia cells in a person, say <10E4
(so-called minimal residual disease [MRD]), the small
volume of blood and bonemarrow samples we test is the key
determinant of whether a MRD test will be positive or
negative rather than test sensitivity. Consequently, in
a personwith CML receiving a tyrosine kinase inhibitor or an
allotransplantation, one would expect results of BCR/ABL1
transcript testing to alternate between positive and negative
based solely on sampling errors, even when numbers of
residual CML cells in that person are constant or decreasing.
This is compatible with the data of Arpinati and comment
by Goldman. This variability in results of MRD testing should
be distinguished from tests that are repeatedly positive,
especially tests which indicate an increasing proportion of
CML cells. This is because at residual leukemia cells >10E4,
test sensitivity, rather than sampling error, predominates.
Namely, because there are many residual leukemia cells in1083-8791/$ e see front matter  2013 American Society for Blood and Marrowimportant corollary is that observations, such as a higher
proportion of leukemia relapses in persons who are
PCR-positive versus those who are PCR-negative, is funda-
mentally a self-fulﬁlling prophesy and does not prove the
PCR test is a reliable surrogate for relapse in persons with few
residual leukemia cells. This incorrect conclusion is common
in interpreting results of MRD testing and not only in persons
with CML.
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5Masonic Cancer Center, University of Minnesota, Minneapolis, MinnesotaWe previously reported that the infusion of ex vivo control subjects [1]. We did not observe an increased inci-
expanded umbilical cord blood (UCB)-derived natural regu-
latory T cells (nTregs) infused immediately after UCB trans-
plantation was associated with a reduced incidence of acute
graft-versus-host disease (GVHD) relative to historicaldence of opportunistic infections or relapse, suggesting the
transient nature of nTreg provided sufﬁcient immune
suppression to control GVHD without long-term deleterious
effects. However, we hypothesized that early side effectsTransplantation.
Figure 1. (A) Cumulative density of infections per 1000 patient-years observed. The median and range of peripheral blood (B) CD19þ, (C) CD3þ/CD8þ, and (D) CD3þ/
CD4þ lymphocytes at day þ180 posttransplantation for nTreg versus in historical control subjects.
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points, such as when adoptively transferred nTregs were
detectable in the peripheral blood of patient. All but 1
patient, receiving an nTreg dose of 10 106/kg on dayþ1 and
3  106/kg on day 15, have been reported [1]. Patient eligi-
bility, conditioning regimen and immune suppression, and
supportive care were reported [1]. In this analysis, the
historical control subjects consisted of a 65-patient subset of
the 108 reported [1] who had post-UCB transplantation T cell
subset phenotype data available using standard procedures.
In contrast to prior analyses that compared the cumula-
tive incidence of opportunistic, in this analysis we studied
infection density that accounts for multiple infections in an
individual patient. We calculated infection density per 1000
patient-days within 180 days by dividing the total number of
infections within the time period by total patient-day
multiplied by 1000 [2]. In our initial report, we demon-
strated that adoptively transferred nTregs were present in
the peripheral blood of patients up to 14 days after the
infusion of fresh and up to 4 days after the infusion of cry-
opreserved product [1]. Notably, in the current study wefound in this early period (days 0 to þ30) that nTregs are
present, there was signiﬁcantly higher cumulative density of
OI in Treg (18.06 infections per 1000 patient-days) as
comparedwith historical control subjects (7.71 infections per
1000 patient-days) patients (univariate RR, 5.35, P ¼ .02)
(Figure 1A). These were essentially viral reactivations with
no effect on the risk of fungal infections. Thus, it is possible
that Treg can increase the risk of infection during the period
of time they are detectable. This contrasts with our initial
report in which we found no difference in the risk OIs as
assessed by the cumulative incidence. In contrast to the ﬁrst
30 days, between days þ31 and þ180 there was similar OI
density in the two groups (7.22/1000 versus 4.22/1000;
univariate RR, 0.58, P ¼ .07) (Figure 1A). Notably, the higher
risk of early infection did not affect nonrelapse mortality
(18% [95% conﬁdence interval [CI], 2% to 34%] versus 10% [95%
CI, 2% to 17%], P ¼ .34) or progression-free survival (33% [95%
CI, 16% to 52%] versus 35% [95% CI, 24% to 47%], P ¼ .93), as
compared with historical control subjects.
The viral infections observed in nTreg patients through
day þ30 were human herpesvirus-6 viremia (HHV6, n ¼ 9),
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upper respiratory infection. The corresponding viral infec-
tions observed in historical control subjects through dayþ30
were HHV-6 viremia (n ¼ 6), cytomegalovirus reactivation
(n ¼ 8), adenovirus gastroenteritis (n ¼ 4), polyoma virus in
the urine (n ¼ 4), enterovirus gastroenteritis (n ¼ 1), and
upper airway respiratory syncytial virus (n ¼ 1). Three of 9
HHV-6 viremia episodes in the Treg group and 2 of 6 in the
historical control group were treated with foscarnet. In our
institution, we observed 69% incidence reactivation of HHV-6
by 6 weeks after UCB transplantation, overall [3]. Thus,
although a high rate of HHV-6 infections in the ﬁrst month is
not unexpected, the higher density of this infection in the
ﬁrst month as compared with similarly treated patients
could be the result of the Treg infusion. However, patients
in a phase I clinical trial are monitored more closely
than patients receiving the standard of care, and we cannot
rule out that our higher infection density is the result of an
observation bias and/or the limited number of Treg
recipients.
A potential beneﬁt of not developing GVHD is the ability
to taper immune suppression sooner, leading to potentially
faster reconstitution of immune reconstitution. However, we
did not observe a signiﬁcant difference between nTreg
patients versus historical control subjects. At day þ180, the
median absolute number of peripheral blood CD19þ cells
was 179/mL (range, 0 to 1160) versus 282/mL (range,1 to 1632)
(P ¼ .54), CD3þ/CD8þ was 58/mL (range, 14 to 645) versus
72/mL (range, 8 to 848) (P ¼ .46), and CD3þ/CD4þ cells was
255/mL (range, 6 to 527) versus 219/mL (range, 27 to 1179)
(P ¼ .48) for nTreg versus historical control subjects,
respectively (Figure 1B-D). In contrast, data on the adoptive
transfer of nTregs in combination with T effector cells in
haploidentical related donor transplantation showed that
antigen-speciﬁc Tcell immunity was observed sooner than in
historical control subjects [4]. This may be secondary to
biological differences between donor types because cord
blood recipients may take longer to achieve adequate
numbers of virus-speciﬁc T cells [5]. Clearly, longer follow-up
and more detailed analysis are required for better under-
standing of lymphocyte subsets reconstitution.In summary, there is potentially a higher viral infection
risk within 30 days of UCB-derived nTregs infusion due to
suppression of the immune response; however, there was no
adverse effect on the longer term outcomes, including later
risk of OIs. Although observation bias is a possibility, our data
suggesting higher density of viral infections argues for close
observation in studies of the adoptive transfer of nTregs to
reduce GVHD in allogeneic hematopoietic cell trans-
plantation and in solid organ transplantation.
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